Zhenming Liu

Shihezi University — China

Computer Science · Physical Sciences

37h-index6.2kcitations278works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(44), Machine Learning in Materials Science(17), Receptor Mechanisms and Signaling(15), Synthesis and biological activity(13), Chemical Synthesis and Analysis(11)

Publications278 total

Explaining Isoform Selectivity of c-Jun N-Terminal Kinase 3 (JNK3) Inhibitors through Its Development and Structural Insights
Journal of Medicinal Chemistry·2025
First quantitative constraints on the Aiyongco Fault: A record of distributed strain in the western Bangong-Nujiang Fault Zone, Tibetan Plateau
Journal of Asian Earth Sciences·2025
Identifying Drug Combinations Associated with Acute Kidney Injury Using FDA Adverse Events Reporting System
Biomedical Journal of Scientific & Technical Research·2025Open Access
Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors
iScience·2025· 1 citedOpen Access
A unified language model bridging <i>de novo</i> and fragment-based 3D molecule design delivers potent CBL-B inhibitors for cancer treatment
2025Open Access
Augmenting Chemokine CCL21 Enhances the Effectiveness of CTLA4 Blockade Immunotherapy for Head and Neck Squamous Carcinoma
Molecular Cancer Therapeutics·2025
Pocket-based molecule generation with an SE(3)-equivariant language model leads to a potent and selective HPK1 inhibitor with <i>in vivo</i> efficacy
2025Open Access
Synthesis and evaluation of a novel inhibitor for the α5‐GABA <sub>A</sub> receptor in the treatment of peripheral neuralgia: Evidence from MD simulation and in vivo studies
British Journal of Pharmacology·2025Open Access
AI-Driven Discovery and Optimization of Positive Allosteric Modulators for NMDA Receptors: Potential Applications in Depression
Journal of Medicinal Chemistry·2025· 1 cited
Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with <i>In Vitro</i> and <i>In Vivo</i> Efficacy against Triple-Negative Breast Cancer
Journal of Medicinal Chemistry·2025
f-BGM enables fungi-specific genome mining in high accuracy and interpretability
2025Open Access
Intratumoral microbiota-derived S1P sensitizes the combination therapy of Capecitabine and Nivolumab
2025Open Access
A robust label-free workflow for the immunoglobulin G subclass site-specific N-glycopeptides and the glycosylation of IgG 2 correlated with colorectal cancer
Talanta·2025· 1 cited
The frameshifting element in coronaviruses: structure, function, and potential as a therapeutic target
Trends in Pharmacological Sciences·2025· 1 cited
DTLCDR: A target-based multimodal fusion deep learning framework for cancer drug response prediction
Journal of Pharmaceutical Analysis·2025· 1 citedOpen Access
Discovery of novel PI3KC2γ inhibitors with high potency, selectivity, and favorable pharmacokinetics for glycogen metabolism regulation
European Journal of Medicinal Chemistry·2025· 1 cited
Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects
Journal of Medicinal Chemistry·2025· 1 cited
Structure-Based Discovery of a Highly Selective, Oral Polo-Like Kinase 1 Inhibitor with Potent Antileukemic Activity
Journal of Medicinal Chemistry·2025· 1 cited
Design, synthesis, and antitumor activity of NSDs inhibitors targeting lung squamous cell carcinoma
European Journal of Medicinal Chemistry·2025· 1 cited
Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis
Journal of Hepatology·2025· 9 cited
page 1 of 14Next →

Frequent Co-authors

Liangren Zhang(24), Hongwei Jin(10), Lihe Zhang(8), Cangxin Zheng(5), Yibo Li(4), Ping Xu(4), Peilin Yu(4), Wei Yang(4), Jianxing Hu(3), Yanxing Wang(3), Jianfeng Pei(3), Luhua Lai(3), Xianghui Yu(3), Guoquan Liu(3), Runtao Li(3), Tong Chen(2), Hongjun Yang(2), Liangren Zhang(2), Luqi Huang(2), Han Wang(2)